Poly ADP-Ribose Polymerase (PARP) inhibitors are long chain containing 17 enzymes that combine several (poly) units of ADP-ribose in a chain and transfer them to the target proteins.
Global PARP Inhibitors Cancer Therapy Market & Clinical Trials Insight 2028 Report Highlights:
- Global PARP Inhibitors Cancer Therapy Market opportunity: > USD 6 Billion
- Commercially Available PARP inhibitors: > 5 Drugs
- Comprehensive Clinical Insight On More Than 35 PARP Drug In Clinical Trials
- Global PARP Clinical Trials Insight by Company, Country, Indication & Phase
- Market Indicators Till 2028
- Approved Drugs Dosage, Sales, Patent, Price Insight
- Approved Drugs Sales Forecast Till 2028
- Global & Regional Market Analysis
- Regional Analysis Based On Drug Approvals: US, Europe, Chna & Japan
Download Report: https://www.kuickresearch.com/report-parp-inhibitors-market
Poly ADP-Ribose Polymerase (PARP) inhibitors are long chain containing 17 enzymes that combine several (poly) units of ADP-ribose in a chain and transfer them to the target proteins. This helps to restore DNA when it is damaged by many factors such as exposure to UV radiation, some anti-cancer drugs and others. PARP inhibitors block an enzyme critical to the repair of single stranded breaks in the DNA. Inhibition of this DNA repair enzyme can lead to cell death, particularly in cancer cells that carry deficiency of other DNA repair pathways. The critical importance of PARP in cancer progression has led to development of several PARP inhibitors in the market.
Till date, there are about 6 PARP inhibitors available globally in the market. Amid these, Olaparib, Niraparib, Rucaparib, and Talazoparib are available globally whereas Pamiparib and Fuzuloparib have been approved only in China. By drug type, Olaparib holds the maximum share in global market which is mainly due to its ability in the management of wide range of cancers including ovarian cancer, pancreatic cancer, breast cancer, and fallopian tube cancer. In addition to this, the drug is approved in several regions including US, Europe, China, Japan, Canada, amongst others. Further, no competition from the generic drug is also boosting this segment from past few years.
Although these drugs have shown encouraging response in the management of cancers, drug resistance is the major challenge to their adoption. To mitigate these challenges, researchers are currently conducting large number of clinical trials evaluating PARP inhibitor as combinational therapy with chemotherapy, radiotherapy, small molecule inhibitors, and immunotherapy. For instance in 2021, Zentalis Pharmaceutical announced collaboration agreement with GlaxoSmithKline. Under the terms of agreement, Zentalis will evaluate the combination of ZN-c3, Zentalis’ oral WEE1 inhibitor product candidate and Zejula in patients with advanced epithelial ovarian cancer. Zentalis is currently conducting clinical studies with ZN-c3 both as a monotherapy and in combination with certain standard of care therapies.
Apart from this, several other industry players are also focusing on the development of companion diagnostic tests which are designed to pair up targeted agent with a cancer patient harboring the defined molecular characteristics which the drug acts upon. The development of companion diagnostics helps in identification of patients which will respond to particular drug. In April 2022, Amoy Diagnostics has entered into master collaboration agreement with AstraZeneca for the development and commercialization of AmoyDx assays that may cover any type of indication or biomarker for companion diagnostic (CDx) use with AstraZeneca medicines globally. The first project to be initiated under the agreement includes development of CDx to identify breast cancer patients with BRCA gene mutations in Europe for Lynparza monotherapy.
As per our report findings, the global PARP inhibitor market is expected to surpass US$ 6 Billion by 2028. The major factors that are contributing to the growth of market are increasing incidence of ovarian and breast cancer and rising number of PARP inhibitor treatment therapies. Additionally, the presence of large number of biopharmaceutical companies operating in the market and their strong pipeline will also propel the growth of market over the estimated timeframe.
This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, pricing, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities.
Contact:
Neeraj Chawla
Kuick research
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com